LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Budget 2021
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS
Business News » World News

AstraZeneca rebuilds cancer drug hopes with new lung data

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
Updated: Sat, Sep 09, 2017
03:38 am
Reuters
RELATED NEWS
Expert Views: BIG! India's retail inflation eases to 4.59% in December Expert Views: BIG! India's retail inflation eases to 4.59% in December
Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands
Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED
Economy, markets, FIIs, chemicals, IT and Pharma - Make money, as India powers to new highs | EXPLAINED    Economy, markets, FIIs, chemicals, IT and Pharma - Make money, as India powers to new highs | EXPLAINED
Setback for China – Trend reversing in favour of India; SFI lands big blow! Know here WHY! Setback for China – Trend reversing in favour of India; SFI lands big blow! Know here WHY!

Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset July`s big clinical trial setback in the disease.

Particularly impressive was the success of the infused immunotherapy medicine Imfinzi in helping non-small cell lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.

Patients in a large clinical trial survived on average 16.8 months without their disease worsening when given the drug, against just 5.6 months for those on placebo.

Solange Peters of the Centre Hospitalier Universitaire Vaudois in Lausanne, who was not involved in the study known as Pacific, told Reuters the advantage of more than 11 months provided by Imfinzi was "absolutely amazing".

It is the first medicine to show superior progression-free survival in such patients. These individuals typically receive a combination of chemotherapy and radiotherapy, but only around 15 percent of them are still alive after five years.

Significantly, while there were more reports of toxicity in patients taking Imfinzi, the level of severe problems was similar in both groups.

"What we hear from the experts is that they think this is practice-changing," AstraZeneca`s CEO Pascal Soriot told reporters.

AstraZeneca had already said that Pacific and another study called Flaura met their pre-defined goals, but the exact scale of the benefits were only disclosed at the European Society for Medical Oncology (ESMO) congress in Madrid.

Analysts believe using Imfinzi in so-called stage III lung cancer opens up an annual sales opportunity worth around $2 billion. The company also has an important lead of two to three years over rivals in this particular area.

However, this market is still smaller than for advanced lung cancer, where a combination of Imfinzi and tremelimumab failed to work as hoped in the Mystic trial.

Early success in Mystic would have given AstraZeneca the chance to establish the first immunotherapy combination in advanced lung cancer, ahead of rivals Bristol-Myers Squibb , Roche and Merck .

The Flaura trial, meanwhile, demonstrated the ability of AstraZeneca’s new pill Tagrisso to hold lung cancer at bay in patients with a certain genetic mutation that is particularly common in Asia.

The study showed Tagrisso, which AstraZeneca has already predicted will become a $4 billion-a-year seller, was significantly better than older medicines that act in a similar way.

Patients on Tagrisso went 18.9 months on average before their disease worsened, against 10.2 months for those given either Roche`s Tarceva or AstraZeneca`s Iressa.

ESMO spokesman Enriqueta Felip of Spain`s Vall d’Hebron Institute of Oncology said Tagrisso`s edge over older medicines and its good tolerability meant it should be considered a new first-line treatment option.

AstraZeneca is now in discussions with global health authorities about seeking marketing approval to extend the use of both Imfinzi and Tagrisso, based on the Pacific and Flaura data.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Economy
RELATED NEWS
Expert Views: BIG! India's retail inflation eases to 4.59% in December Expert Views: BIG! India's retail inflation eases to 4.59% in December
Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands Budget 2021 Expectations – HOME BUYERS to benefit if Govt accepts this demand; JLL CEO lists following demands
Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED Jobs, land prices, Covid-19 vaccine, rural India, household savings, NBFCs, banks, consumption, capex - Positives and Negatives | EXPLAINED
Economy, markets, FIIs, chemicals, IT and Pharma - Make money, as India powers to new highs | EXPLAINED    Economy, markets, FIIs, chemicals, IT and Pharma - Make money, as India powers to new highs | EXPLAINED
Setback for China – Trend reversing in favour of India; SFI lands big blow! Know here WHY! Setback for China – Trend reversing in favour of India; SFI lands big blow! Know here WHY!

LATEST NEWS

Big Yes Bank initiative for MSME! Up to Rs 5 cr collateral-free funds made available

Mindtree share price: ICICI Securities downgrades stock to ADD (from BUY), price target Rs 1661

Tata Consumer Products share price: Eyeing growth outdoors as Covid fears ease II Sharekhan revises price target to Rs 685

Larsen and Toubro, KEC International, Kalpataru Power Transmission II Key stocks to watch out in Budget from Capital Goods sector

PUBG Mobile India: Launch date, trailer, competition from FAUG and other latest updates

Bank Interest Rate: Important message for these bank account holders released today

7th Pay Commission latest news: Salary Rs 67,700 to over Rs 2 lakh plus 7th CPC DA, HRA, TA; check this central government job offer at upsconline.gov.in

Pay through your nose for Traffic Violations! Your auto insurance premium set to be hiked I All details explained

HDFC Securities says 14040-14215 band is the next support area for Nifty while 14358 could act as a resistance

WhatsApp Web users' Phone numbers available on Google Search? Know how to stop it

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved